{"organizations": [], "uuid": "a274ee8f01149c1b0ada9ecb12b9b6ee604160b4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "https://si.wsj.net/img/WSJ_Logo_black_social.gif", "site_section": "https://www.wsj.com/europe", "section_title": "The Wall Street Journal &amp; Breaking News, Business, Financial and Economic News, World News and Video", "url": "https://www.wsj.com/articles/ironwood-will-separate-from-its-rare-disease-drug-unit-after-shareholder-pressure-1525204887", "country": "US", "domain_rank": 387, "title": "Ironwood Will Separate From Its Rare-Disease Drug Unit After Shareholder Pressure", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-02T00:01:00.000+03:00", "replies_count": 0, "uuid": "a274ee8f01149c1b0ada9ecb12b9b6ee604160b4"}, "author": "Jonathan D. Rockoff", "url": "https://www.wsj.com/articles/ironwood-will-separate-from-its-rare-disease-drug-unit-after-shareholder-pressure-1525204887", "ord_in_thread": 0, "title": "Ironwood Will Separate From Its Rare-Disease Drug Unit After Shareholder Pressure", "locations": [], "entities": {"persons": [{"name": "peter hecht", "sentiment": "none"}], "locations": [], "organizations": [{"name": "sarissa capital management", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Ironwood Pharmaceuticals said it will put the rare-disease drugs it has been developing into a new business, an unusual move that the company hopes will reset its value following pressure from shareholders and an activist investor.\nThe separation, the structure of which is still to be determined, is expected to be completed in the first half of next year. It will leave Ironwood as a traditional drugmaker focused on selling medications for irritable bowel syndrome, gout and reflux disease, with the goal of earning regular profits... ", "external_links": ["http://phx.corporate-ir.net/phoenix.zhtml?c=228069&p=RssLanding&cat=news&id=2345876&mod=article_inline", "http://phx.corporate-ir.net/phoenix.zhtml?c=228069&p=RssLanding&cat=news&id=2345875&mod=article_inline", "https://www.fiercepharma.com/pharma/ironwood-has-a-new-wannabe-director-activist-investor-alex-denner?mod=article_inline"], "published": "2018-05-02T00:01:00.000+03:00", "crawled": "2018-05-02T01:02:04.028+03:00", "highlightTitle": ""}